Winterlight Labs announced a collaboration with Janssen Pharmaceuticals, facilitated by Johnson & Johnson Innovation, which will focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's Disease, from healthy elderly subjects.